Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.

ABSTRACT:

Background

The development of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates among patients with Philadelphia chromosome (Ph+) B cell acute lymphoblastic leukemia (B-ALL). Ph-like B-ALL patients lack the BCR::ABL1 translocation but share gene expression profiles with Ph+ B-ALL. The role of TKIs for Ph-like patients pre- and post-hematopoietic stem cell transplantation (HSCT) is not yet clear.

Case

Here we present five cases of pediatric, adolescent, and young adult patients who presented with Ph-like B-ALL or CML in B-ALL blast phase who were treated with personalized TKI regimens pre- and post-HSCT.

Conclusion

This report describes several novel Ph-like fusions as well as combinations of TKIs with chemotherapy or immunotherapy not yet rep

SUBMITTER: Shumock SS 

PROVIDER: S-EPMC10728537 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature